AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05203783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Application
Description: Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
Study NCT05403502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 1.5
Description: t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
Study NCT04745052 — intervention group
Intervention type: OTHER
Intervention: Clinical observation index
Description: The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
Study NCT05624918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Study NCT05624918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Study NCT05960396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
Study NCT04915404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berubicin Hydrochloride
Description: Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
Study NCT06063486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06063486 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06063486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06063486 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06063486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06063486 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT06063486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement
Description: Given PO
Study NCT06063486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Piperine Extract (Standardized)
Description: Given PO
Study NCT06063486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT06063486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06063486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04060407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD24Fc
Description: CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
Study NCT04060407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
Study NCT04060407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
Study NCT05929872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: ACTIVE transcranial direct current stimulation( tDCS)
Study NCT02801318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Polysomnography
Study NCT04935021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATTR-CM
Description: Current treatment
Study NCT05326503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal matrix with polyphenol supplement (PPS)
Description: Test meal with polyphenol supplement
Study NCT05326503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal matrix with placebo
Description: Test meal with placebo (maltodextrin) supplement
Study NCT05326503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No meal matrix with PPS
Description: Test drink with polyphenol supplement
Study NCT05326503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No meal matrix with placebo
Description: Test drink with placebo (maltodextrin) supplement
Study NCT05453942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
Study NCT05453942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
Study NCT05624918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T(P)
Description: Worn > 18 hr /day starting C1D1 until completion of cycle 3
Study NCT05929872 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham non-invasive brain stimulation
Description: SHAM tDCS
Study NCT06019715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Remote Physical Activity Intervention
Description: Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
Study NCT05985525 — intervention group
Intervention type: DEVICE
Intervention: Skeletal muscle and cerebral NIRS (research device)
Description: NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
Study NCT05492552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active-at-home-HF
Description: Increase daily step count by 2,000 and weekly telephone calls.
Study NCT05300126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
Study NCT05020470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Auricular Point Acupressure (APA)
Description: Participants will learn how to self-administer APA by themselves.
Study NCT05020470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Person Training
Description: Participants will receive in-person training to self-administer APA.
Study NCT05020470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will continue to do whatever they are instructed by theirs physicians.
Study NCT05331326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
Study NCT05113186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)
Study NCT05886374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-415S1
Description: HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
Study NCT06471686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 2 pills three times a day
Study NCT06231186 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iHD-SRT
Description: received isotoxic individualized fSRT, with BED 10>50Gy and \<100Gy, and strict OAR limits
Study NCT04761770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) pre-transplant
Description: Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
Study NCT04761770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conditioning regimen
Description: Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -> Myeloablative (MA) regimen~2. HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen
Study NCT04761770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic CD34+ selected stem cells
Description: Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
Study NCT06114927 — intervention group
Intervention type: BEHAVIORAL
Intervention: Validation of a questionnaire
Description: The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
Study NCT05728398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music played within the fluoroscopy suite during an interventional radiology procedure.
Study NCT05728398 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Music
Description: No music played within the fluoroscopy suite during an interventional radiology procedure.
Study NCT05015569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COVR Medical Garment
Description: COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team.
Study NCT05015569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Gown
Description: The standard patient gown is provided to all patients in a hospital setting.
Study NCT05223049 — intervention group
Intervention type: OTHER
Intervention: painDETECT questionnaire
Description: The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
Study NCT05223049 — intervention group
Intervention type: OTHER
Intervention: Douleur Neuropathique 4 questionnaire (DN4)
Description: DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
Study NCT05223049 — intervention group
Intervention type: OTHER
Intervention: Short form-36
Description: The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
Study NCT05223049 — intervention group
Intervention type: OTHER
Intervention: Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)
Description: SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
Study NCT05223049 — intervention group
Intervention type: OTHER
Intervention: Numeric Rating Scale
Description: Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
Study NCT05223049 — intervention group
Intervention type: OTHER
Intervention: Disease activity in psoriatic arthritis (DAPSA)
Description: DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
Study NCT05030350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B
Description: Nasal spray
Study NCT05448482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator tape
Description: Mid urethral sling for treatment of female stress urinary incontinence
Study NCT05448482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturator tape
Description: Mid urethral sling for treatment of female stress urinary incontinence
Study NCT04802265 — intervention group
Intervention type: PROCEDURE
Intervention: Epiretinal membrane surgery
Description: The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser.
Study NCT06388005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional freedom technique (EFT)
Description: The emotional freedom technique (EFT), founded by American scholar Gary Craig, is based on the methods of meridian science in traditional Chinese medicine (TCM) and Western psychology. Guided by the TCM theory of meridians, it quickly releases negative emotions by combining acupoint stimulation with neuro-linguistic programming, and its effectiveness has been confirmed by multiple studies.
Study NCT05965375 — intervention group
Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.
Study NCT05794334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dye Taping
Description: This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
Study NCT06488482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab or pembrolizumab
Description: See above
Study NCT06488482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab or pembrolizumab
Description: See above
Study NCT06307275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
Study NCT06307275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non fasting
Description: Participants will not be fasting during these four weeks. They will eat their normal food intake and keep their normal physical activity levels.
Study NCT04877275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (80mg/d)
Description: Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;
Study NCT04877275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (100mg/d)
Description: Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;
Study NCT04877275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 25 mg/m\^2 intravenously on day 1 , QW
Study NCT04877275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg/d QW
Study NCT04877275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide：300mg/m2, d1 QW，
Study NCT05533853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posture corrective exercises
Description: The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
Study NCT05533853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denneroll extension traction
Description: The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
Study NCT06152991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GODEX
Description: The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg
Study NCT06152991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg.
Study NCT05351346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05351346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05351346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.